Genmab — December 2017
-
Fakta er også at W og JJ har ramt spot on, i forhold til at vurdere salget for 2017. Det er faktisk ret imponerende, med så mange faktorer der spiller ind, og så stor en udrulning. Måske det var en ide at tage de lidt længere briller på, og acceptere at vækstkurven flader ud i ny og næ - den langsigtede trend peger op, og der er endnu ingen grund til bekymring. W træder engang imellem ved siden af, men din evige kritik af ham, er helt ved siden af. Han har gjort det fantastisk
-
Robert Wu @balanceview "The corporate tax cuts will make royalty payments more expensive. Royalty are before tax expenses so governments pays 35%. Now it is 20%. It may make sense for some to takeover instead of to pay royalty. $jnj #genmab, $ions, $biib."
-
on FDA lifting hold PD-(L)1 https://www.biopharmadive.com/news/fda-lifts-clinical-hold-checkpoint-inhibitors-multiple-myeloma/512404/
-
Hahaha
-
Jeg er stadig ikke helt kommet mig over dine forecasts på receptdata
-
JanssenUS @JanssenUS · 32 min.
"We can't wait to share new DARZALEX (daratumumab) data in just a few days! Check out what we have in store as you get ready for #ASH17 http://po.st/8v1Bfq "
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind